1 – 27 of 27
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
- 2022
-
Mark
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma : a study of younger patients from the MCL2 and MCL3 clinical trials
(
- Contribution to journal › Article
-
Mark
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
(
- Contribution to journal › Article
- 2021
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
(
- Contribution to journal › Article
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article
- 2020
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
(
- Contribution to journal › Article
- 2019
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
(
- Contribution to journal › Article
- 2018
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
(
- Contribution to journal › Article
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
- 2015
-
Mark
Emerging role of SOX11 in mantle cell lymphoma
(
- Contribution to journal › Scientific review
- 2014
-
Mark
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study.
(
- Contribution to journal › Article
- 2012
-
Mark
Expanded clinical and experimental use of SOX11-using a monoclonal antibody
(
- Contribution to journal › Article
- 2010
-
Mark
Identification of uniquely expressed transcription factors in highly purified B-cell lymphoma samples.
(
- Contribution to journal › Article
-
Mark
SOX11 expression correlates to promoter methylatuion and regulates tumor growth in hematopoietic malignancies
(
- Contribution to journal › Article
- 2009
-
Mark
Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells.
(
- Contribution to journal › Article
- 2008
-
Mark
Transformed diffuse large B cell lymphomas differ from follicular lymphomas in both gene and protein expression
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Nuclear expression of the Non-B Cell Lineage Sox11 Transcription Factor Identifies Mantle Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
Sox11, a non-B cell lineage transcription factor, is overexpressed in mantle cell lymphoma
2008) 10th International Conference on Malignant Lymphoma In Annals of Oncology 19(Suppl. 4). p.172-173(
- Contribution to journal › Published meeting abstract
-
Mark
B cell lymphomas express CX(3)CR1 a non-B cell lineage adhesion molecule.
(
- Contribution to journal › Article
- 2005
-
Mark
High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma
(
- Contribution to journal › Article